Loading…
Regentis Biomaterials Ltd. is projected to rise to $4.27 by 2027, a +15% move from its current price of $3.79. RGNT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.33 | $3.79 | $4.32 | +0.04% |
| Jul 14 | $3.15 | $3.79 | $4.56 | +0.08% |
| Jul 15 | $3.02 | $3.79 | $4.76 | +0.12% |
| Jul 16 | $2.92 | $3.80 | $4.93 | +0.16% |
| Jul 17 | $2.83 | $3.80 | $5.09 | +0.20% |
| Jul 18 | $2.76 | $3.80 | $5.23 | +0.24% |
| Jul 19 | $2.69 | $3.80 | $5.37 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.69 | $3.80 | $5.37 | +0.28% |
| Week 2 | $2.34 | $3.81 | $6.22 | +0.56% |
| Week 3 | $2.10 | $3.82 | $6.96 | +0.84% |
| Week 4 | $1.92 | $3.83 | $7.66 | +1.12% |
| Week 5 | $1.77 | $3.84 | $8.33 | +1.40% |
| Week 6 | $1.65 | $3.85 | $9.00 | +1.68% |
| Week 7 | $1.55 | $3.86 | $9.66 | +1.96% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee.
The company was incorporated in 2004 and is based in Herzliya, Israel.
Regentis Biomaterials Ltd. (RGNT) is currently priced at $3.64 per share and has a market capitalization of $25.61M, ranking 4827. The stock trades within a 30-day technical range of $1.40 to $9.48, with a near-term support at $1.28 and resistance at $9.40. RSI16 sits at 50, indicating neutral momentum and a balanced near-term stance.
Forecasts show a path of gradual price evolution with an initial neutral stance into 2026, followed by a shift to bullish momentum in later years. The 2026 avg is $3.64, with 2027 avg $4.20 and 2028 avg $3.98. By 2030 the avg is $3.34 and ROI is -8.1%, with sentiment Neutral, and the outlook improves markedly as the years progress, reaching notable bullish readings in 2033-2035 and through 2040 and 2050, where avg prices reach into the high $5s and into the high $7s with double-digit ROI.
A major floor 66.2% below — a decisive break under it would weaken the trend.
The nearest floor, 66.2% below — buyers have tended to step in here.
The nearest ceiling, 148.0% above — a clean break opens room to run.
A major ceiling 241.5% above — clearing it would confirm fresh momentum.
Key RGNT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RGNT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.72 | Buy | $3.76 | Buy |
| MA 10 | $3.84 | Sell | $3.83 | Sell |
| MA 20 | $4.15 | Sell | $3.71 | Buy |
| MA 50 | $2.92 | Buy | $3.36 | Buy |
| MA 100 | $3.10 | Buy | $3.63 | Buy |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.65 | Neutral |
| Stoch RSI (14) | 24.11 | Neutral |
| CCI (20) | -28.37 | Neutral |
| Williams %R (14) | -75.00 | Info |
| MACD (12,26,9) | -0.12 | Sell |
| ROC (12) | -9.76 | Sell |
| Bollinger %B (20,2) | 0.44 | Neutral |
| Stochastic %K (14) | 25.00 | Neutral |
| TRIX (15) | 1.78 | Buy |
| Awesome (5,34) | 0.51 | Buy |
| Ultimate (7,14,28) | 51.76 | Neutral |
| Momentum (10) | -0.36 | Sell |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 3.56 | Buy |
| ADX (14) | 14.11 | Neutral |
| ATR (14) | 0.48 | Info |
The near-term technical picture is Neutral. The RSI14 is 50, and the 50-day simple moving average is $2.88, suggesting a balance between buying and selling pressures.
The stock sits in a 30-day range from $1.40 to $9.48, with a defined support at $1.28 and resistance at $9.40. This setup indicates a wide swing potential in the near term, with relatively limited directional bias.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.28 | $3.73 | $5.65 | 0% | Neutral | |
| $2.79 | $4.27 | $7.07 | +15% | Neutral | |
| $2.39 | $4.06 | $7.32 | +9% | Neutral | |
| $2.09 | $3.89 | $7.47 | +4% | Neutral | |
| $1.68 | $3.41 | $6.89 | -9% | Neutral | |
| $1.45 | $3.21 | $6.80 | -14% | Neutral | |
| $2.01 | $4.46 | $9.80 | +20% | Neutral | |
| $2.34 | $5.19 | $11.82 | +39% | Bullish | |
| $2.38 | $5.29 | $12.17 | +42% | Bullish | |
| $2.23 | $4.96 | $11.41 | +33% | Bullish | |
| $3.45 | $7.67 | $17.65 | +106% | Bullish | |
| $3.57 | $7.93 | $18.25 | +113% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.28 | $3.73 | $4.99 | -1.72% |
| August 2026 | $3.25 | $4.05 | $5.33 | +8.84% |
| September 2026 | $3.09 | $3.93 | $5.32 | -3.08% |
| October 2026 | $3.13 | $4.06 | $5.63 | +3.29% |
| November 2026 | $3.17 | $4.17 | $5.91 | +2.85% |
| December 2026 | $2.93 | $3.92 | $5.65 | -6.12% |
Click any year to see its month-by-month RGNT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RGNT could reach as high as $5.65, with a base case around $3.73 and support toward $1.28 — roughly 0% from $3.79. Price action looks broadly range-bound.
Expect RGNT to range from $2.79 to $7.07 through 2027. The $4.27 average target implies a +15% move from current prices. That is up +15% on the projected 2026 average. A consolidation phase looks the most probable path here.
The RGNT price prediction for 2028 points to an average of $4.06 (low $2.39, high $7.32) — a potential gain of +9% on today's $3.79. Price action looks broadly range-bound.
In 2029, RGNT is projected to trade between $2.09 and $7.47, averaging $3.89 — a potential gain of +4% from today's $3.79. That is -4% versus the projected 2028 average. A consolidation phase looks the most probable path here.
Regentis Biomaterials Ltd.'s 2030 outlook centres on $3.41, within a $1.68 to $6.89 range. That is -12% versus the projected 2029 average. That marks a -9% change versus current levels. Price action looks broadly range-bound.
By 2031, RGNT could reach as high as $6.80, with a base case around $3.21 and support toward $1.45 — roughly -14% from $3.79. A consolidation phase looks the most probable path here.
Expect RGNT to range from $2.01 to $9.80 through 2032. The $4.46 average target implies a +20% move from current prices. That is up +39% on the projected 2031 average. Price action looks broadly range-bound.
The RGNT price prediction for 2033 points to an average of $5.19 (low $2.34, high $11.82) — a potential gain of +39% on today's $3.79. Buyers look set to stay in control over this stretch.
In 2034, RGNT is projected to trade between $2.38 and $12.17, averaging $5.29 — a potential gain of +42% from today's $3.79. That is up +2% on the projected 2033 average. Momentum favours further upside here.
Regentis Biomaterials Ltd.'s 2035 outlook centres on $4.96, within a $2.23 to $11.41 range. That is -6% versus the projected 2034 average. That marks a +33% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, RGNT could reach as high as $17.65, with a base case around $7.67 and support toward $3.45 — roughly +106% from $3.79. Momentum favours further upside here.
Expect RGNT to range from $3.57 to $18.25 through 2050. The $7.93 average target implies a +113% move from current prices. That is up +3% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in RGNT today (≈ 263.852243 RGNT) could be worth
$2,093.38
+$1,093.38 (+109%) by 2050 · US Dollar
Based on the average projected RGNT price of $7.93 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RGNTwould be worth at today's price.
$1,000 invested in RGNT on Dec 4, 2025 (≈ 133.333333 RGNT) would be worth
$505.33
-$494.67 (-49.5%) today · 0.51× · US Dollar
Based on a RGNT entry price of $7.5 vs. today's $3.79.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.03 | $940.45 | -6.0% |
| 1 month ago | $1.76 | $2,153.41 | +115.3% |
| 3 months ago | $3.1 | $1,222.58 | +22.3% |
| 6 months ago | $6.35 | $596.85 | -40.3% |
| All time ago | $7.5 | $505.33 | -49.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RGNT forecast.
Our base-case forecast reaches $7.60 around 2040.
Implied market cap at $7.60: $53.38M
The multi-year forecast shows a journey from neutral to bullish sentiment over time, with distinct turning points. In 2026 the min, avg, and max are $1.28, $3.64, and $5.49, with ROI of 0 and neutral sentiment.
From 2027 through 2029, the average price trends higher to $4.20, $3.98, and $3.77 respectively, with ROI of 15.3, 9.4, and 3.5, all still bearing neutral sentiment.
The forecast turns negative in 2030 and 2031, with avg prices of $3.34 and $3.15 and ROI of -8.1 and -13.6, still neutral. A bullish shift begins in 2032 with an avg of $4.35 and ROI of 19.4, followed by stronger upside in 2033 ($5.11 avg, ROI 40.3) and 2034 ($5.16 avg, ROI 41.6), then 2035 ($4.82 avg, ROI 32.3).
The bullish trajectory continues into 2040 with an avg of $7.51 and ROI of 106.2, and into 2050 with an avg of $7.66 and ROI of 110.5, both marked as bullish sentiment. These figures illustrate a long-run upside despite near-term volatility.
Tap a question to reveal the answer.
2030: min $1.65, avg $3.34, max $6.77, ROI -8.1, sentiment NEUTRAL.
Forecasts show neutral in 2026 with ROI 0 and 2027-2029 positive ROI (15.3, 9.4, 3.5). From 2033 onward the outlook is bullish with stronger upside, though 2030-2031 show negative ROI (-8.1, -13.6). These are estimates, not guarantees.
Yes. The forecast lists 2033 max $11.63 and 2034 max $11.86, indicating potential to exceed $11 in those years.
$1.40 to $9.48.
Current price is $3.64 and market cap is $25.61M.
Regentis Biomaterials Ltd. Community Discussion
0Share your Regentis Biomaterials Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.